Top Industry Leaders in the Endoprosthesis Market
Disclaimer: List of key companies in no particular orderLatest Endoprostheses Companies Update
-
July 2023: Johnson & Johnson is the most recent pharmaceutical company to file a lawsuit against the US government to thwart a policy that grants the Medicare government-run healthcare plan the authority to bargain for reduced prescription pricing. The pharmaceutical industry claims that President Joe Biden signed the Inflation Reduction Act bill, which will force drugmakers to halt the research of novel therapies and reduce revenues through a medication price negotiating scheme. The Biden administration intends to save $25 billion yearly by 2031 by having Medicare negotiate costs for some of the most expensive medications used by its beneficiaries, who are 65 and older. Americans spend more money than any other nation on prescription drugs.
-
Aug 2023: The rating agency AM Best has given managing general agents (MGAs) Corin Underwriting Limited (UK) and Corin Underwriting (Europe) GmbH (Corin Europe) a performance evaluation of PA-3 (Strong), with a stable outlook. As a result, Corin is the first MGA of its size in the UK to receive such a high-performance rating from Best. Best claims that the evaluation considers several distinct elements, such as Corin's great underwriting skills, superior governance and internal controls, sound financial standing, strong organizational aptitude, and strong depth and breadth of partnerships.
List of Endoprostheses Key companies in the market
-
Johnson & Johnson Services, Inc. (US)
-
Zimmer Biomet Holdings Inc. (US)
-
Stryker (US)
-
Smith & Nephew (UK)
-
Corin Ltd (UK)
-
Medacta International SA (Switzerland)
-
Exactech, inc. (US)
-
MicroPort Orthopedics, Inc. (US)
-
Baumer S.A. (Switzerland)
-
B. Braun Melsungen AG (Germany)